Iteos Therapeutics Inc (ITOS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Iteos Therapeutics Inc (ITOS) has a cash flow conversion efficiency ratio of -0.086x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-42.45 Million) by net assets ($493.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Iteos Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
Iteos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Iteos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Iteos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iteos Therapeutics Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Iteos Therapeutics Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wuhan Ligong Guangke Co Ltd
SHE:300557
|
0.008x |
|
Changshu Ruite Electric Co Ltd
SHE:300600
|
0.998x |
|
People & Technology Inc
KQ:137400
|
0.023x |
|
Verano Holdings Corp
NEO:VRNO
|
0.045x |
|
Aic Mines Ltd
AU:A1M
|
0.175x |
|
EUROKAI GmbH & Co. KGaA
F:EUK3
|
0.017x |
|
Gourmet Master Co Ltd
TW:2723
|
0.067x |
|
Dongguan Chitwing Technology Co Ltd
SHE:002855
|
0.242x |
Annual Cash Flow Conversion Efficiency for Iteos Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Iteos Therapeutics Inc from 2018 to 2024. View current stock price of Iteos Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $590.29 Million | $-98.18 Million | -0.166x | +7.79% |
| 2023-12-31 | $575.23 Million | $-103.76 Million | -0.180x | -7.60% |
| 2022-12-31 | $663.33 Million | $-111.19 Million | -0.168x | -118.06% |
| 2021-12-31 | $552.82 Million | $513.14 Million | 0.928x | +1291.61% |
| 2020-12-31 | $323.20 Million | $-25.18 Million | -0.078x | +94.73% |
| 2019-12-31 | $15.67 Million | $-23.14 Million | -1.477x | -16.43% |
| 2018-12-31 | $15.05 Million | $-19.10 Million | -1.269x | -- |
About Iteos Therapeutics Inc
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lym… Read more